Production (Stage)
NLS Pharmaceutics AG
NLSP
$2.30
$0.2210.58%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 101.21% | 101.21% | 73.26% | 73.26% | 41.96% |
| Total Depreciation and Amortization | -141.38% | -141.38% | 0.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1,475.47% | -1,475.47% | 120.89% | 120.89% | -80.55% |
| Change in Net Operating Assets | -116.24% | -116.24% | 50.79% | 50.79% | 207.49% |
| Cash from Operations | -14.63% | -14.63% | 79.03% | 79.03% | 61.57% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | 6.78% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 135.89% | 135.89% | -- | -- | -88.17% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | 200.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 247.60% | 247.60% | 95.27% | 95.27% | -109.93% |